Home » Reports » Broker Ratings » AstraZeneca plc 9.7% Potential Upside Indicated by Barclays Capital
broker ratings

AstraZeneca plc 9.7% Potential Upside Indicated by Barclays Capital

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ this morning by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 6800 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 9.7% from today’s opening price of 6199 GBX. Over the last 30 and 90 trading days the company share price has increased 224 points and increased 219 points respectively. The 1 year high for the share price is 6432.48 GBX while the year low share price is currently 4544.5 GBX.

AstraZeneca plc has a 50 day moving average of 5,913.02 GBX and a 200 day moving average of 5,473.53. There are currently 1,266,798,130 shares in issue with the average daily volume traded being 2,799,241. Market capitalisation for LON:AZN is £78,465,480,198 GBP.